Navigation Links
Researchers prolong the plasma half-life of biopharmaceutical proteins
Date:9/21/2009

Many biopharmaceuticals comprise small proteins that are quickly eliminated from the body. Scientists at the Technische Universitaet Muenchen (TUM) combine such small proteins with a kind of molecular balloon that swells and thus prolongs the half-life of the proteins in the body. The TUM spin-off XL-protein GmbH has now started to further develop this new technology with blockbuster potential.

People who suffer from hepatitis B are often treated with the tissue hormone interferon. However, there is a problem: Interferon is a very small protein, which is filtered from the blood via the kidneys after only a short time. For the patient this means a high-dose injection every other day to keep the effect of the substance from wearing off prematurely.

However, interferon stays in the body much longer when chemically coupled with a synthetic PEG (polyethylene glycol) molecule. PEG is a random coil long-chain polymer string that swells by adsorbing water. That way the PEG molecule becomes large enough that it does not fit through the fine pores of the kidneys the attached interferon remains in the circulatory system longer, and the patient will need an injection only every one to two weeks.

Using genetic engineering, TU Muenchen scientist Prof. Arne Skerra and his coworkers from the Chair of Biological Chemistry at the Center for Life and Food Sciences Weihenstephan have now developed an amino acid string that tangles up similarly to PEG and also swells in the presence of water. However, unlike many PEG compounds, there is no danger of this biological polymer accumulating in the body. In fact over an extended period of time it is discharged or biologically broken down. That happens because this amino acid string (polypeptide) consists of three of the 20 naturally occurring amino acids: proline, alanine and serine, or in short, PAS.

The protein substance interferon, which itself consists of amino acids, can thus be easily generated in "PASylated" form. In first trials with animals, TUM scientists established that PASyated interferon has a half-life in the blood that is prolonged by a factor of 60, which should allow a significant extension of dosing intervals during medicinal therapy.

A further advantage is the simplified biotechnological production: The DNA segments carrying the information for the PAS amino acid sequence and for the interferon can simply be attached to each other and then, for instance, used for transforming bacteria. The bacteria then produce the PASylated interferon in one piece, thus making much fewer production steps necessary in comparison with the chemical coupling of PEG. According to Skerra, "this will lead to a significant drop in production cost."

In principle all small proteins currently used as medication or in development in pharmaceutical companies for example, growth factors or functional antibody fragments can be PASylated. Thus there could be a huge market for the new technology. Consequently, Prof. Skerra and his team initiated the founding of a new biotech company, XL-protein GmbH (http://www.xl-protein.com), which started its operations last spring. "Our technology has the potential to give birth to a whole new generation of blockbuster medications," the TUM biochemist is convinced. Several of the new drugs are already at an advanced stage of preclinical development.


'/>"/>

Contact: Patrick Regan
presse@zv.tum.de
49-892-892-2743
Technische Universitaet Muenchen
Source:Eurekalert

Related biology technology :

1. Researchers improve ability to write and store information on electronic devices
2. Long-awaited international ethical guidelines for biobank researchers
3. CU researchers shed light on light-emitting nanodevice
4. Stevens researchers provide new information about mass spectrometry
5. Researchers measure carbon nanotube interaction
6. Researchers underscore limitations of genetic ancestry tests
7. ASU researchers improve memory devices using nanotech
8. UD researchers race ahead with latest spintronics achievement
9. Researchers outline structure of largest nonvirus particle ever crystallized
10. Ames Laboratory researchers solve fuel-cell membrane structure conundrum
11. Researchers use magnetism to target cells to animal arteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family ... and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... and administered by the New York Academy of Sciences to honor the excellence ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):